COPENHAGEN, Denmark, May 13, 2023 (GLOBE NEWSWIRE) – Ascendis Pharma A/S ASND announced today that the Company will present clinical and research findings on hypoparathyroidism and growth hormone deficiency, as well as host an information booth and events, at ECE 2023, the European Congress of Endocrinology, being held May 13-16 in Istanbul, Turkey. ECE brings together international professionals to share the latest scientific knowledge and clinical practices in the fields of endocrinology and metabolism.
“Ascendis is committed to developing novel therapies with best-in-class safety, efficacy, tolerability and convenience,” said Jan Mikkelsen, President and Chief Executive Officer of Ascendis Pharma. “We are excited to showcase our advanced endocrinology portfolio, the meaningful difference we make for patients, and our work to bring new treatment options to the European Union.”
The following are Ascendis Pharma’s five posters at ECE 2023:
| ABSTRACT | PRESENTING AUTHOR | |
| hypoparathyroidism | ||
|
Christopher Sibley, MD
poster |
|
|
Christopher Sibley, MD
Program code: P301 |
|
| growth hormone deficiency | ||
|
Nils Berg Madsen, Ph.D.
e-poster |
|
|
Aleksandra… |
[ad_2]
Source story
